REVIEW ARTICLE Rian J. Dickstein, Ashish M. Kamat, MD; ONCOLOGY Vol. 25 No. 14 Muscle-invasive bladder cancer is an aggressive and potentially lethal disease. Integration of multimodal therapies, improved surgical techniques, and utilization of targeted agents has tremendously improved outcomes.
CLINICAL QUANDARIES Waseem Khaliq, Ikechukwu Uzoaru, et al; ONCOLOGY Vol. 24 No. 9 Here we present the first case of a radiation-resistant solitary plasmacytoma of the bladder that was successfully treated with lenalidomide and dexamethasone with successful clinical remission.
SECOND OPINION Thomas W. Flaig, Francisco G. La Rosa, et al;ONCOLOGY Vol. 23 No. 2 The patient is a 39-year-old man who presents with pelvic lymphadenopathy. He has a history of ureteral reflux disease, recurrent nephrolithiasis, right nephrectomy, ileal loop diversion of the left ureter, and radical cystectomy for “bladder cancer,” which he underwent 3 years ago. The lymphadenopathy was discovered incidentally during recent imaging.
Bladder cancer was the fourth most common and eighth most deadly cancer in males in the United States in 2012, with an estimated 55,600 new cases and... More »
In a trial of 64 patients, neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine, and cisplatin (MVAC) had promising results in the... More »
The use of presurgical characteristics to assign the clinical stage of a patient with bladder cancer was found to be highly inaccurate with a... More »
Researchers have identified bladder cancer markers that can predict which patients may have the most aggressive, fatal type of the disease. It was... More »
Primary Care Can't Thrive Without Nurse Practitioners Courtney H. Lyder, ND, May 17, 2013 With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
Muscle-invasive bladder cancer is an aggressive and potentially lethal disease. Integration of multimodal therapies, improved surgical techniques, and utilization of targeted agents has tremendously improved outcomes.
This article reviews existing management paradigms and challenges in bladder cancer treatment today. Also a discussion on personalized medicine, molecular and cellular pathogenesis, and molecular therapies.
This review highlights the biology of therapeutic fever-range hyperthermia, and summarizes the data supporting the role of hyperthermia in the management of bladder cancer.
Here we present the first case of a radiation-resistant solitary plasmacytoma of the bladder that was successfully treated with lenalidomide and dexamethasone with successful clinical remission.
